Palovarotene

(Sohonos®)

Sohonos®

Drug updated on 12/19/2023

Dosage FormCapsule (oral; 1, 1.5, 2.5, 5, 10 mg)
Drug ClassRetinoids
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For reduction in the volume of new heterotopic ossification in adults and children aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressive

Product Monograph / Prescribing Information

Document TitleYearSource
Sohonos (palovarotene) Prescribing Information.2023Ipsen Biopharmaceuticals, Cambridge, MA

Randomized Controlled Trials


Sex Distribution:

F:46%
M:54%
210Subjects

Year:

2023

Source:Journal of Bone and Mineral Research


Sex Distribution:

F:55%
M:45%
40Subjects

Year:

2022

Source:Journal of Bone and Mineral Research